MTOR and esophageal cancer: At the same time, some literature has confirmed that Phosphatidylinositol 3-kinase/AKT/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) can be used as an immunotherapy target for esophageal cancer by affecting the expression of microRNA [30].